|
ES2280826T5
(es)
|
2002-08-05 |
2017-08-03 |
Silence Therapeutics Gmbh |
Nuevas formas adicionales de moléculas de ARN de interferencia
|
|
US7892793B2
(en)
*
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
|
ES2712695T3
(es)
|
2003-06-02 |
2019-05-14 |
Univ Massachusetts |
Métodos y composiciones para controlar la eficacia de la silenciación del ARN
|
|
AU2004252442B2
(en)
*
|
2003-06-02 |
2010-04-08 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of FNAi
|
|
WO2005027980A1
(en)
*
|
2003-09-12 |
2005-03-31 |
University Of Massachusetts |
Rna interference for the treatment of gain-of-function disorders
|
|
US8680063B2
(en)
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
|
US20060134787A1
(en)
|
2004-12-22 |
2006-06-22 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
|
|
US8084599B2
(en)
|
2004-03-15 |
2011-12-27 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
US20070265220A1
(en)
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
JP2009504782A
(ja)
|
2005-08-18 |
2009-02-05 |
アルナイラム ファーマシューティカルズ インコーポレイテッド |
神経疾患を治療するための方法および組成物
|
|
SI2056845T1
(en)
|
2006-08-08 |
2018-02-28 |
Rheinische Friedrich-Wilhelms-Universitaet Bonn |
STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES
|
|
WO2008143774A2
(en)
*
|
2007-05-01 |
2008-11-27 |
University Of Massachusetts |
Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
|
|
EP2297323A1
(en)
|
2008-05-21 |
2011-03-23 |
Hartmann, Gunther |
5' triphosphate oligonucleotide with blunt end and uses thereof
|
|
TWI455944B
(zh)
*
|
2008-07-01 |
2014-10-11 |
Daiichi Sankyo Co Ltd |
雙股多核苷酸
|
|
US9089610B2
(en)
|
2008-08-19 |
2015-07-28 |
Nektar Therapeutics |
Complexes of small-interfering nucleic acids
|
|
US8225729B2
(en)
*
|
2008-12-16 |
2012-07-24 |
Kimberly-Clark Worldwide, Inc. |
Three-dimensional wiping substrate and method therefor
|
|
EP2379083B1
(en)
*
|
2008-12-18 |
2017-08-16 |
Dicerna Pharmaceuticals, Inc. |
Extended dicer substrate agents and methods for the specific inhibition of gene expression
|
|
US11414664B2
(en)
|
2008-12-18 |
2022-08-16 |
Dicerna Pharmaceuticals, Inc. |
Extended dicer substrate agents and methods for the specific inhibition of gene expression
|
|
WO2010093788A2
(en)
|
2009-02-11 |
2010-08-19 |
Dicerna Pharmaceuticals, Inc. |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
WO2010111471A2
(en)
*
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
EP2756845B1
(en)
|
2009-04-03 |
2017-03-15 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
|
|
ES2628144T3
(es)
|
2009-04-03 |
2017-08-01 |
Dicerna Pharmaceuticals, Inc. |
Métodos y composiciones para la inhibición específica de KRAS por RNA bicatenario asimétrico
|
|
WO2011005363A2
(en)
*
|
2009-05-18 |
2011-01-13 |
Ensysce Biosciences, Inc. |
Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
|
|
WO2010141933A1
(en)
*
|
2009-06-05 |
2010-12-09 |
Dicerna Pharmaceuticals, Inc. |
Specific inhibition of gene expression by nucleic acid containing a dicer substrate
|
|
EP2440666B1
(en)
|
2009-06-10 |
2017-03-01 |
Temasek Life Sciences Laboratory Limited |
Virus induced gene silencing (vigs) for functional analysis of genes in cotton
|
|
US8283333B2
(en)
|
2009-07-01 |
2012-10-09 |
Protiva Biotherapeutics, Inc. |
Lipid formulations for nucleic acid delivery
|
|
WO2011011447A1
(en)
|
2009-07-20 |
2011-01-27 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing ebola virus gene expression
|
|
US8916693B2
(en)
|
2009-09-17 |
2014-12-23 |
Nektar Therapeutics |
Monoconjugated chitosans as delivery agents for small interfering nucleic acids
|
|
CA2775092A1
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
JP5685267B2
(ja)
|
2009-12-09 |
2015-03-18 |
日東電工株式会社 |
Ｈｓｐ４７発現の調節
|
|
WO2011072292A2
(en)
*
|
2009-12-11 |
2011-06-16 |
Dicerna Pharmaceuticals, Inc. |
Phase changing formulations of rna and rna derivatives
|
|
JP5257796B2
(ja)
*
|
2009-12-28 |
2013-08-07 |
株式会社村田製作所 |
固体電解コンデンサ素子及びその製造方法
|
|
CA2804210A1
(en)
|
2010-07-06 |
2012-01-12 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna
|
|
EP2591105B1
(en)
|
2010-07-06 |
2017-05-31 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
ES3005233T3
(en)
|
2010-10-01 |
2025-03-14 |
Modernatx Inc |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
|
WO2012056440A1
(en)
*
|
2010-10-28 |
2012-05-03 |
Nanodoc Ltd. |
COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA
|
|
EP2681314B1
(en)
|
2011-03-03 |
2017-11-01 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treating lung disease and injury
|
|
EP2508530A1
(en)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
EP2718442B1
(en)
|
2011-06-10 |
2017-07-12 |
Temasek Life Sciences Laboratory Limited |
Genetic manipulation and expression systems for pucciniomycotina and ustilaginomycotina subphyla
|
|
WO2012173994A2
(en)
*
|
2011-06-15 |
2012-12-20 |
Dicerna Pharmaceuticals, Inc. |
Phase changing formulations of nucleic acid payloads
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2763701B1
(en)
|
2011-10-03 |
2018-12-19 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
ES2745373T3
(es)
|
2011-10-18 |
2020-03-02 |
Dicerna Pharmaceuticals Inc |
Lípidos catiónicos de amina y uso de los mismos
|
|
IL303831A
(en)
|
2011-11-18 |
2023-08-01 |
Alnylam Pharmaceuticals Inc |
Adapted RNAI factors
|
|
JP2015501844A
(ja)
|
2011-12-16 |
2015-01-19 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
DK2817287T3
(da)
|
2012-02-24 |
2019-01-02 |
Arbutus Biopharma Corp |
Trialkyl kationisk lipid og metoder til anvendelse deraf
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
CN104797712B
(zh)
|
2012-04-19 |
2018-06-12 |
淡马锡生命科学研究院有限公司 |
提高棉纤维长度的方法
|
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
|
ES2921623T3
(es)
|
2012-11-26 |
2022-08-30 |
Modernatx Inc |
ARN modificado terminalmente
|
|
WO2014093746A2
(en)
*
|
2012-12-14 |
2014-06-19 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of ckap5 by double-stranded rna
|
|
EP2968149B1
(en)
|
2013-03-14 |
2024-05-08 |
Dicerna Pharmaceuticals, Inc. |
Process for formulating an anionic agent
|
|
ES2882110T3
(es)
|
2013-03-14 |
2021-12-01 |
Translate Bio Inc |
Métodos y composiciones para administrar anticuerpos codificados con ARNm
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
EP3017047A4
(en)
|
2013-07-03 |
2017-06-14 |
Dicerna Pharmaceuticals Inc. |
Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded rna
|
|
WO2015020960A1
(en)
|
2013-08-09 |
2015-02-12 |
Novartis Ag |
Novel lncrna polynucleotides
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
US10150965B2
(en)
|
2013-12-06 |
2018-12-11 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
|
|
US9701966B2
(en)
|
2013-12-27 |
2017-07-11 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
|
|
JP6688292B2
(ja)
|
2014-10-10 |
2020-04-28 |
ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
乳酸デヒドロゲナーゼ及びその薬剤の治療的阻害
|
|
US10266837B2
(en)
|
2014-10-22 |
2019-04-23 |
Temasek Life Sciences Laboratory Limited |
Terpene synthases from ylang ylang (Cananga odorata var. fruticosa)
|
|
ES2747842T3
(es)
|
2014-12-15 |
2020-03-11 |
Dicerna Pharmaceuticals Inc |
Acidos nucleicos de doble hebra modificados por ligando
|
|
US10036017B2
(en)
|
2015-02-17 |
2018-07-31 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
|
|
WO2016183009A2
(en)
|
2015-05-08 |
2016-11-17 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of antithrombin 3 (at3) by double-stranded rna
|
|
CA2991052A1
(en)
*
|
2015-07-02 |
2017-01-05 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
|
WO2018045317A1
(en)
|
2016-09-02 |
2018-03-08 |
Dicerna Pharmaceuticals, Inc. |
4'-phosphate analogs and oligonucleotides comprising the same
|
|
EP3696270A4
(en)
*
|
2017-10-11 |
2021-07-07 |
Nitto Denko Corporation |
REGULATION OF THE EXPRESSION OF NUCLEIC ACID MOLECULES
|
|
IL273875B2
(en)
|
2017-10-13 |
2025-07-01 |
Dicerna Pharmaceuticals Inc |
Methods and compositions for inhibiting expression of ldha
|
|
HRP20230023T1
(hr)
|
2017-10-20 |
2023-03-17 |
Dicerna Pharmaceuticals, Inc. |
Postupci liječenja infekcije hepatitisom b
|
|
JP2021509669A
(ja)
|
2018-01-05 |
2021-04-01 |
ディセルナ ファーマシューティカルズ インコーポレイテッド |
免疫療法を強化するためのベータ−カテニン及びｉｄｏの発現の低減
|
|
WO2019143621A1
(en)
|
2018-01-16 |
2019-07-25 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting aldh2 expression
|
|
JP7616987B2
(ja)
|
2018-07-13 |
2025-01-17 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド
|
|
WO2020051231A1
(en)
|
2018-09-04 |
2020-03-12 |
H. Lee Moffitt Cancer Center & Research Institute Inc. |
Use of delta-tocotrienol for treating cancer
|
|
WO2020142693A1
(en)
*
|
2019-01-04 |
2020-07-09 |
Empirico Inc. |
Treatment of thymic stromal lymphopoietin (tslp) related diseases by inhibition of long-form tslp transcripts
|
|
EP3908661A1
(en)
|
2019-02-12 |
2021-11-17 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for inhibiting expression of cyp27a1
|
|
SG11202110174PA
(en)
|
2019-03-29 |
2021-10-28 |
Dicerna Pharmaceuticals Inc |
Compositions and methods for the treatment of kras associated diseases or disorders
|
|
WO2020206350A1
(en)
|
2019-04-04 |
2020-10-08 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting gene expression in the central nervous system
|
|
AU2020268798A1
(en)
|
2019-05-03 |
2021-11-04 |
Dicerna Pharmaceuticals, Inc. |
Double-stranded nucleic acid inhibitor molecules with shortened sense strands
|
|
CN114867733A
(zh)
|
2019-08-30 |
2022-08-05 |
迪克纳制药公司 |
配体-2’-修饰核酸、其合成和其中间体化合物
|
|
AU2020358016A1
(en)
|
2019-10-02 |
2022-04-21 |
Dicerna Pharmaceuticals, Inc. |
Chemical modifications of small interfering RNA with minimal fluorine content
|
|
AU2020410993A1
(en)
|
2019-12-24 |
2022-06-16 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
|
|
CN114828852A
(zh)
|
2019-12-24 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合
|
|
US20230287425A1
(en)
|
2020-03-18 |
2023-09-14 |
Dicerna Pharmacuticals Inc. |
Compositions and methods for inhibiting angptl3 expression
|
|
AU2021321430A1
(en)
|
2020-08-04 |
2023-03-02 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting PLP1 expression
|
|
TW202221120A
(zh)
|
2020-08-04 |
2022-06-01 |
美商黛瑟納製藥公司 |
用於治療代謝症候群之組成物及方法
|
|
CA3187220A1
(en)
|
2020-08-04 |
2022-02-10 |
Dicerna Pharmaceuticals, Inc. |
Systemic delivery of oligonucleotides
|
|
AU2021322891A1
(en)
|
2020-08-05 |
2023-03-09 |
Dicerna Pharmaceuticals, Inc. |
Oligonucleotide treatment of hepatitis B patients
|
|
TW202535432A
(zh)
|
2020-08-05 |
2025-09-16 |
美商戴瑟納製藥股份有限公司 |
抑制lpa表現之組合物及方法
|
|
CA3214439A1
(en)
|
2021-04-12 |
2022-10-20 |
Boehringer Ingelheim International Gmbh |
Compositions and methods for inhibiting ketohexokinase (khk)
|
|
WO2022221430A1
(en)
|
2021-04-14 |
2022-10-20 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for modulating pnpla3 expression
|
|
MX2023012086A
(es)
|
2021-04-19 |
2023-10-25 |
Novo Nordisk As |
Composiciones y metodos para inhibir la expresion del miembro 3 del grupo h de la subfamilia 1 de receptores nucleares (nr1h3).
|
|
MX2023013504A
(es)
|
2021-05-28 |
2024-02-23 |
Novo Nordisk As |
Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1).
|
|
TW202308660A
(zh)
|
2021-08-25 |
2023-03-01 |
美商戴瑟納製藥股份有限公司 |
用於抑制α－１抗胰蛋白酶表現之組合物及方法
|
|
IL312635A
(en)
|
2021-11-11 |
2024-07-01 |
Hoffmann La Roche |
Pharmaceutical combinations for treatment of hbv
|
|
EP4441218A2
(en)
|
2021-12-01 |
2024-10-09 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for modulating apoc3 expression
|
|
CA3245064A1
(en)
|
2022-04-15 |
2023-10-19 |
Dicerna Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS OF MODULATING THE ACTIVITY OF STRUCTURAL AND CYTOSKELETON-ASSOCIATED PROTEINS
|
|
EP4522747A1
(en)
|
2022-05-12 |
2025-03-19 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting mapt expression
|
|
US20230416743A1
(en)
|
2022-05-13 |
2023-12-28 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting snca expression
|
|
TWI868755B
(zh)
|
2022-06-24 |
2025-01-01 |
丹麥商諾佛 儂迪克股份有限公司 |
抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法
|
|
WO2024040041A1
(en)
|
2022-08-15 |
2024-02-22 |
Dicerna Pharmaceuticals, Inc. |
Regulation of activity of rnai molecules
|
|
TW202430637A
(zh)
|
2022-11-16 |
2024-08-01 |
美商戴瑟納製藥股份有限公司 |
Stat3靶向性寡核苷酸及其用途
|
|
AR133386A1
(es)
|
2023-07-28 |
2025-09-24 |
Dicerna Pharmaceuticals Inc |
Composiciones y métodos para la expresión del receptor del ligando de muerte programada (pd-l1)
|
|
WO2025054459A1
(en)
|
2023-09-08 |
2025-03-13 |
Dicerna Pharmaceuticals, Inc. |
Rnai oligonucleotide conjugates
|
|
WO2025133951A1
(en)
|
2023-12-21 |
2025-06-26 |
Genevant Sciences Gmbh |
Ionizable lipids suitable for lipid nanoparticles
|
|
WO2026022656A2
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Lipid particle formulations with permanently charged cationic lipids
|
|
WO2026022677A1
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Permanently charged cationic lipids
|
|
WO2026041910A2
(en)
|
2024-08-21 |
2026-02-26 |
Novo Nordisk A/S |
Compositions and methods for inhibiting xdh expression
|
|
WO2026083241A1
(en)
|
2024-10-15 |
2026-04-23 |
Genevant Sciences Gmbh |
Ionizable lipids comprising n,n-substituted hydroxylamine esters
|